Labcorp Holdings Inc.
Labcorp Holdings Inc.
Your view on LH
Overview
What the company does, where it operates, and who runs it.
About Labcorp Holdings Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Adam H. Schechter
- Headquarters
- 358 South Main Street, Burlington, NC, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Adam H. Schechter
- Headquarters
- 358 South Main Street, Burlington, NC, US
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Labcorp Holdings Inc. from FRC's valuation model, read against the market price. LH last traded at $372.46, 30.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Labcorp Holdings Inc.. Starting points for Labcorp Holdings Inc.: P/E 30.3, EPS $12.38, beta 0.84 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Labcorp Holdings Inc.. Labcorp Holdings Inc. paid $2.88 per share over the last year — a 0.8% yield at the current $372.46 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Labcorp Holdings Inc.. Trailing twelve-month EPS for Labcorp Holdings Inc. stands at $12.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$373.55
average of 11 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy7
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $4.50 | $4.54 | $18.51 | $19.74 |
| Low estimate | $4.46 | $4.38 | $18.32 | $18.87 |
| High estimate | $4.56 | $4.65 | $18.61 | $20.08 |
| No. of analysts | 10 | 7 | 10 | 12 |
| Year-ago EPS | $4.07 | $4.25 | $10.46 | — |
| Growth | +10.6% | +6.8% | +76.9% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $3.75B | $3.73B | $14.83B | $15.64B |
| Low estimate | $3.71B | $3.70B | $14.76B | $15.41B |
| High estimate | $3.77B | $3.74B | $14.87B | $15.82B |
| No. of analysts | 8 | 6 | 8 | 13 |
| Year-ago revenue | $3.52B | $3.54B | $13.95B | — |
| Growth | +6.7% | +5.5% | +6.3% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Labcorp Holdings Inc.. Labcorp Holdings Inc. has reported as a listed company since 1990. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- BMXXYbioMérieux S.A.Medical - Diagnostics & Research$17.2B
- DGXQuest Diagnostics IncorporatedMedical - Diagnostics & Research$28.8B
- ERFSFEurofins Scientific SEMedical - Diagnostics & Research$14.4B
- GHGuardant Health, Inc.Medical - Diagnostics & Research$19.5B
- GRALGRAIL, Inc.Medical - Diagnostics & Research$4.7B
- NTRANatera, Inc.Medical - Diagnostics & Research$41.8B
- QGENQiagen N.V.Medical - Diagnostics & Research$10.3B
- SKHCFSonic Healthcare LimitedMedical - Diagnostics & Research$7.9B
More Medical - Diagnostics & Research companies
- VCYTVeracyte, Inc.NASDAQ$1.9B
- VIMGFVimian Group AB (publ)OTC$1.5B
- VRCDFVerici Dx plcOTC$5M
- WATWaters CorporationNYSE$44.6B
- WGSGeneDx Holdings Corp.NASDAQ$1.5B
- WUXAYWuXi AppTec Co., Ltd.OTC$45.6B
- WUXIFWuXi AppTec Co., Ltd.OTC$39.8B
- XGNExagen Inc.NASDAQ$96M
- SKHHYSonic Healthcare LimitedOTC$8.2B
- SLDXStella Diagnostics Inc.OTC$1M
- SPDESpeedus Corp.OTC$416
- SZLSFStageZero Life Sciences Ltd.OTC$61,766
ETFs holding Labcorp Holdings Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.04%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.04%
- VOVanguard Mid-Cap ETF$103.4B in assets0.28%
- IVViShares Core SP 500 ETF$852.9B in assets0.05%
- SPYState Street SPDR S&P 500 ETF Trust$818.5B in assets0.05%
- BASVBrown Advisory Sustainable Value ETF$434M in assets2.05%
- FXHFirst Trust Health Care AlphaDEX Fund$1.2B in assets1.54%
- SPLVInvesco S&P 500 Low Volatility ETF$7.5B in assets0.96%
Largest holders first, then the funds most concentrated in LH.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Labcorp Holdings Inc., and how their positions are changing. At a $30.24B market value, institutional positions materially move Labcorp Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Labcorp Holdings Inc. executives and directors. Shares of Labcorp Holdings Inc. have traded between $209.38 and $293.72 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Labcorp Holdings Inc.. Labcorp Holdings Inc. is a $30.24B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Labcorp Holdings Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Labcorp Holdings Inc.. Coverage tracks Labcorp Holdings Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Labcorp Holdings Inc.